本文已被:浏览 191次 下载 198次
Received:June 06, 2023 Published Online:March 20, 2024
Received:June 06, 2023 Published Online:March 20, 2024
中文摘要: 膜增生性肾小球肾炎(MPGN)是以肾小球系膜细胞增生及系膜基质沿内皮细胞和毛细血管基底膜插入而形成“双轨征”为主要特征的肾脏病理类型,免疫球蛋白(包括免疫复合物、单克隆免疫球蛋白等)沉积是其损伤机制之一。该病主要临床表现为蛋白尿(多为大量蛋白尿)、高血压、肾性血尿及肾功能受损,且常伴有低补体血症,预后较差,现有诊疗方案对该病的疗效尚不确切。利妥昔单抗是一种抗B细胞表面抗原CD20的特异性人鼠嵌合型单克隆抗体。近年来,部分国内外学者将利妥昔单抗应用于免疫球蛋白介导的MPGN,本文对此进行总结,以期为免疫球蛋白介导的MPGN的临床治疗提供参考。
Abstract:Membranoproliferative glomerulonephritis (MPGN) is a renal pathological type characterized by the proliferation of mesangial cells and the insertion of mesangial matrix along endothelial cells and capillary basement membranes, forming a “double track sign”. The deposition of immunoglobulins (including immune complexes, monoclonal immunoglobulins, etc.) is one of its damage mechanisms. The main clinical manifestations of this disease are proteinuria (mostly a large amount of proteinuria), hypertension, renal hematuria, and impaired renal function, often accompanied by hypocomplementaemia, with poor prognosis. The efficacy of existing diagnostic and treatment plans for this disease is still uncertain. Rituximab is a specific human mouse chimeric monoclonal antibody against the B-cell surface antigen CD20. In recent years, some domestic and foreign scholars have applied rituximab to immunoglobulin mediated MPGN. Therefore, this article summarizes this in order to provide reference for the clinical treatment of immunoglobulin mediated MPGN.
keywords: Membranoproliferative glomerulonephritis Rituximab Immunoglobulin deposition Immune complexes Monoclonal immunoglobulin Hepatitis C virus Autoimmune diseases
文章编号: 中图分类号:R629.3+1 文献标志码:A
基金项目:国家自然科学基金资助项目(82004316,81473447)
引用文本: